View Post

Rare Patient Voice: Study Opportunity for Breast Cancer Female Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 minute Web-Assisted Phone Interview Compensation $200 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why …

View Post

Team discovers novel strategy to tame aggressive breast cancer and starts clinical trial

In Clinical Studies News by Barbara Jacoby

By: National Cancer Centre Singapore From: medicalxpress.com A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less …

View Post

Clinical Challenges: Surgery for De Novo Metastatic Breast Cancer?

In In The News by Barbara Jacoby

By: Diana Swift From: medpagetoday.com Questions remain about whether there is any benefit to removing an intact primary tumor About 6% of newly diagnosed breast cancer patients present at initial diagnosis with de novo metastatic disease and an intact primary tumor. Understandably, many such patients will want to have that tumor removed at the outset. Over the past 2 decades, …

View Post

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

From: prnewswire.com Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that, based on the compelling results observed in part one, it has initiated part two of its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in …

View Post

Navigating the Ins and Outs of Implant Reconstruction After Breast Cancer Surgery

In In The News by Barbara Jacoby

By: Darlene Dobkowski, MA From: curetoday.com Different breast implant options and potential complications may make the reconstruction process difficult to understand, but one expert discusses the importance of knowing what you want and hopefully avoiding postsurgical issues. Women with breast cancer who undergo surgery as part of their treatment may also undergo implant-based reconstruction, which can come with its own …

View Post

Medications deemed essential to breast cancer prevention

In In The News by Barbara Jacoby

By: Richard Gawel From: healio.com Medication can play an essential role in breast cancer prevention, Holly J. Pederson, MD, director of medical breast services at the Cleveland Clinic, said during the NAMS Annual Meeting. “My objectives… are to identify women who will benefit most from risk-reducing medications, to recognize the importance of comorbid conditions and the timing of therapy and …

View Post

Defence Therapeutics embark on next stage of breast cancer treatment development

In Clinical Studies News by Barbara Jacoby

From: healtheuropa.eu In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase 1 trial for its innovative AccuTOX breast cancer treatment. AccuTOX is one of Defence Therapeutics‘ premier candidates for effective breast cancer treatment and is comprised of the company’s cutting-edge AccumTM technology platform, which was …

View Post

C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities

In In The News by Barbara Jacoby

Source: Accuray Incorporated From: prnewswire.com C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement designed to enhance the Accuray Radixact® System’s ability to treat breast cancer. The companies will partner to provide customers with a solution for deep inspiration breath hold (DIBH)* using the C-RAD Catalyst+ HD and Radixact System. DIBH …

View Post

Clinical Challenges: When to Start End-of-Life Care in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Leah Lawrence From: medpagetoday.com Breast cancer remains the second leading cause of cancer death among women in the U.S. Although treatments for metastatic breast cancer — whether a new diagnosis or recurrent disease — have improved in recent years, metastatic disease remains incurable, explained Dawn L. Hershman, MD, MS, director of breast oncology at the Herbert Irving Comprehensive Cancer …